IPG Investment Advisors LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

IPG Investment Advisors LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) in the third quarter, Holdings Channel reports. The firm acquired 1,655 shares of the medical research company’s stock, valued at approximately $838,000.

Several other hedge funds also recently added to or reduced their stakes in TMO. Cornerstone Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 1.7% in the third quarter. Cornerstone Advisors LLC now owns 17,700 shares of the medical research company’s stock valued at $8,959,000 after acquiring an additional 300 shares in the last quarter. Rhenman & Partners Asset Management AB lifted its holdings in Thermo Fisher Scientific by 10,900.0% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 55,000 shares of the medical research company’s stock worth $27,839,000 after buying an additional 54,500 shares during the last quarter. Sonen Capital LLC boosted its position in shares of Thermo Fisher Scientific by 3.8% in the 3rd quarter. Sonen Capital LLC now owns 1,801 shares of the medical research company’s stock valued at $912,000 after purchasing an additional 66 shares during the period. Tocqueville Asset Management L.P. raised its stake in Thermo Fisher Scientific by 11.8% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 93,598 shares of the medical research company’s stock valued at $47,377,000 after acquiring an additional 9,875 shares during the last quarter. Finally, Navellier & Associates Inc. purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $466,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. 0.32% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Down 0.5 %

Thermo Fisher Scientific stock traded down $2.68 during mid-day trading on Monday, reaching $548.07. The company’s stock had a trading volume of 535,619 shares, compared to its average volume of 1,928,942. The company has a market capitalization of $211.76 billion, a price-to-earnings ratio of 35.65, a price-to-earnings-growth ratio of 2.31 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $593.17. The business’s 50 day simple moving average is $533.33 and its 200 day simple moving average is $513.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same quarter in the previous year, the firm posted $5.40 EPS. Thermo Fisher Scientific’s revenue was down 4.9% compared to the same quarter last year. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.57 earnings per share for the current year.

Thermo Fisher Scientific announced that its board has initiated a share repurchase program on Tuesday, November 14th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2.2% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TMO. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Thursday, October 26th. Stifel Nicolaus decreased their price target on Thermo Fisher Scientific from $660.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, October 26th. KeyCorp cut Thermo Fisher Scientific from an “overweight” rating to a “sector weight” rating in a report on Thursday, October 26th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Finally, HSBC started coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $596.00.

Get Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.